FDA Expands Gene Therapy for Younger Patients - Quiz - MDSpire

FDA Expands Gene Therapy for Younger Patients

Exagamglogene autotemcel is now indicated for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.

  • By

  • Kathryn Wighton

  • July 2, 2026

  • 3 min

Share

Original Source(s)

FDA Expands Gene Therapy for Younger Patients

  • by Kathryn Wighton

  • July 2, 2026

Related Content

QTc interval prolongation in pediatric eating disorder population

Venous malformation with localized intravascular coagulopathy in children treated with sclerotherapy and LWMH

Correction: Pulmonary cryptococcosis with cavitation in an immunocompetent child: a case report and literature review